Compare PAR & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | SLDB |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 759.8M |
| IPO Year | 1995 | 2017 |
| Metric | PAR | SLDB |
|---|---|---|
| Price | $14.54 | $6.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $33.20 | $16.36 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $455,547,000.00 | $8,094,000.00 |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $3.07 |
| 52 Week High | $72.15 | $8.87 |
| Indicator | PAR | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 46.21 |
| Support Level | $13.85 | $6.58 |
| Resistance Level | $15.10 | $6.97 |
| Average True Range (ATR) | 0.98 | 0.47 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 49.88 | 44.56 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.